The Immunohistochemistry Facility (IHC) provides support for basic research in cellular structure/function, as well as translational research in clinical applications and molecular medicine. The IHC serves the faculty in the Cancer Research Center by providing state-of-the-art immunohistochemistry and immunofluorescence technology, as well as primary processing of tissues for histologic sectioning and routine hematoxylin and eosin staining. The Facility has three goals: (1) to provide routine histologic and immunohistochemical services in a timely manner using cutting-edge technology and expertise;(2) to evaluate and implement new techniques and stains for development; and (3) to provide education. Routine services include processing of tissues to paraffin blocks, paraffin and frozen sections, routine hematoxylin and eosin staining, and a variety of immunohistochemical and immunofluorescent stains utilizing state-of-the-art instrumentation and a broad array of available characterized antibodies. Technology and application development is nurtured by a close relationship with Cancer Research Center investigators who produce novel antibodies and reagents in the course of their research. The laboratory also is an educational resource for investigators and graduate students who are unfamiliar with handling animal tissues and/or with the techniques used by the Core Facility;this activity frequently requires consultation, one-on-one training sessions, and advice on protocol development. Overall usage of the IHC has increased significantly since the 2001 CCSG submission with significant recent expansion;the number of projects performed in 2006 totaled three times the number performed the previous year. Currently, over 35 peer-reviewed UCCRC investigators across all six Scientific Programs routinely utilize the IHC, totaling 70% of Facility usage.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-N)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Li, Gang; Montgomery, Jeffrey E; Eckert, Mark A et al. (2017) An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun 8:1775
Stoddart, Angela; Wang, Jianghong; Hu, Chunmei et al. (2017) Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model. Blood 129:2959-2970
Wing, Claudia; Komatsu, Masaaki; Delaney, Shannon M et al. (2017) Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. Stem Cell Res 22:79-88
Shah, Palak; Trinh, Elaine; Qiang, Lei et al. (2017) Arsenic Induces p62 Expression to Form a Positive Feedback Loop with Nrf2 in Human Epidermal Keratinocytes: Implications for Preventing Arsenic-Induced Skin Cancer. Molecules 22:
Qiang, Lei; Sample, Ashley; Shea, Christopher R et al. (2017) Autophagy gene ATG7 regulates ultraviolet radiation-induced inflammation and skin tumorigenesis. Autophagy 13:2086-2103
Morita, Shuhei; Villalta, S Armando; Feldman, Hannah C et al. (2017) Targeting ABL-IRE1? Signaling Spares ER-Stressed Pancreatic ? Cells to Reverse Autoimmune Diabetes. Cell Metab 25:1207
Davis, Trevor L; Rebay, Ilaria (2017) Antagonistic regulation of the second mitotic wave by Eyes absent-Sine oculis and Combgap coordinates proliferation and specification in the Drosophila retina. Development 144:2640-2651
Kathayat, Rahul S; Elvira, Pablo D; Dickinson, Bryan C (2017) A fluorescent probe for cysteine depalmitoylation reveals dynamic APT signaling. Nat Chem Biol 13:150-152
Hu, Xue; Li, Li; Yu, Xinyi et al. (2017) CRISPR/Cas9-mediated reversibly immortalized mouse bone marrow stromal stem cells (BMSCs) retain multipotent features of mesenchymal stem cells (MSCs). Oncotarget 8:111847-111865
Hasan, Yasmin; Waller, Joseph; Yao, Katharine et al. (2017) Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat 162:317-328

Showing the most recent 10 out of 613 publications